Download Gene Section MXI1 (MAX interactor 1) Atlas of Genetics and Cytogenetics

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Epigenetics of diabetes Type 2 wikipedia , lookup

Saethre–Chotzen syndrome wikipedia , lookup

Mutagen wikipedia , lookup

Epigenetics of neurodegenerative diseases wikipedia , lookup

Frameshift mutation wikipedia , lookup

Epistasis wikipedia , lookup

Gene desert wikipedia , lookup

Gene wikipedia , lookup

Long non-coding RNA wikipedia , lookup

Neuronal ceroid lipofuscinosis wikipedia , lookup

Gene therapy wikipedia , lookup

Gene expression programming wikipedia , lookup

Epigenetics of human development wikipedia , lookup

Mutation wikipedia , lookup

Primary transcript wikipedia , lookup

Gene nomenclature wikipedia , lookup

Gene therapy of the human retina wikipedia , lookup

Vectors in gene therapy wikipedia , lookup

Gene expression profiling wikipedia , lookup

Cancer epigenetics wikipedia , lookup

Site-specific recombinase technology wikipedia , lookup

Microevolution wikipedia , lookup

Nutriepigenomics wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

Genome (book) wikipedia , lookup

Polycomb Group Proteins and Cancer wikipedia , lookup

RNA-Seq wikipedia , lookup

Designer baby wikipedia , lookup

Mir-92 microRNA precursor family wikipedia , lookup

Therapeutic gene modulation wikipedia , lookup

Point mutation wikipedia , lookup

Oncogenomics wikipedia , lookup

NEDD9 wikipedia , lookup

Transcript
Atlas of Genetics and Cytogenetics
in Oncology and Haematology
OPEN ACCESS JOURNAL AT INIST-CNRS
Gene Section
Mini Review
MXI1 (MAX interactor 1)
Niels B Atkin
Department of Cancer Research, Mount Vernon Hospital, Northwood, Middlesex, UK (NBA)
Published in Atlas Database: December 1999
Online updated version : http://AtlasGeneticsOncology.org/Genes/MXI1ID209.html
DOI: 10.4267/2042/37556
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 1999 Atlas of Genetics and Cytogenetics in Oncology and Haematology
Homology
Identity
Belongs to the basic helix-loop-helix (bhlh) family of
transcription factors.
HGNC (Hugo): MXI1
Location: 10q24-25
Mutations
DNA/RNA
Somatic
Description
Mutations have been described in some sporadic
prostate cancers but no germline mutations were found
in a study of 38 families with possible predisposition to
this disease; a correlation between a polymorphic
repeat in the 3' untranslated region in Mxil mRNA and
regulation of its transcription and degradation has been
suggested.
The gene spans approximately 60 kb; 6 exons.
Transcription
2.6 kb mRNA; two transcription initiation sites.
Protein
Description
Implicated in
228 amino acids; 26 kDa; contains a basic region/helixloop-helix/leucine zipper (B-HLH-LZ) motif that is
similar to that found in Myc family.
Implicated in some sporadic cases of prostate
cancer and glioblastoma as a tumour
suppressor gene
Expression
Tissue specific;
differentiation.
induced
during
cells
References
terminal
Zervos AS, Gyuris J, Brent R. Mxi1, a protein that specifically
interacts with Max to bind Myc-Max recognition sites. Cell.
1993 Jan 29;72(2):223-32
Localisation
Nuclear.
Albarosa R, DiDonato S, Finocchiaro G. Redefinition of the
coding sequence of the MXI1 gene and identification of a
polymorphic repeat in the 3' non-coding region that allows the
detection of loss of heterozygosity of chromosome 10q25 in
glioblastomas. Hum Genet. 1995 Jun;95(6):709-11
Function
Mxil, discovered in 1993, is, with Mad, one of the
proteins that can regulate Max, a human protein
containing a basic helix-loop-helix leucine zipper
(bHLH-zip) that allows the formation of cMyc-Max
heterodimers and that activates transcription; Mad and
Mxil may be involved in tumour suppression since they
can compete with Myc proteins for the interaction with
Max; Mxil normally functions to suppress cell growth:
experimental induction of the gene resulted in the
accumulation of cells in G2-M phase.
Atlas Genet Cytogenet Oncol Haematol. 1999; 3(4)
Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB,
Prochownik EV. Mutation of the MXI1 gene in prostate cancer.
Nat Genet. 1995 Mar;9(3):249-55
Kawamata N, Park D, Wilczynski S, Yokota J, Koeffler HP.
Point mutations of the Mxil gene are rare in prostate cancers.
Prostate. 1996 Sep;29(3):191-3
Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang
ZF, Cordon-Cardo C. Microsatellite instability and deletion
analysis of chromosome 10 in human prostate cancer. Int J
Cancer. 1996 Apr 22;69(2):110-3
185
MXI1 MAX interactor 1
Atkin NB
Shimizu E, Shirasawa H, Kodama K, Sato T, Simizu B.
Expression, regulation and polymorphism of the mxi1 genes.
Gene. 1996 Oct 17;176(1-2):45-8
Benson LQ, Coon MR, Krueger LM, Han GC, Sarnaik AA,
Wechsler DS. Expression of MXI1, a Myc antagonist, is
regulated by Sp1 and AP2. J Biol Chem. 1999 Oct
1;274(40):28794-802
Edwards SM, Dearnaley DP, Ardern-Jones A, Hamoudi RA,
Easton DF, Ford D, Shearer R, Dowe A, Eeles RA. No
germline mutations in the dimerization domain of MXI1 in
prostate cancer clusters. The CRC/BPG UK Familial Prostate
Cancer
Study
Collaborators.
Cancer
Research
Campaign/British
Prostate
Group.
Br
J
Cancer.
1997;76(8):992-1000
Foley KP, Eisenman RN. Two MAD tails: what the recent
knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD
network. Biochim Biophys Acta. 1999 May 31;1423(3):M37-47
Lee TC, Ziff EB. Mxi1 is a repressor of the c-Myc promoter and
reverses activation by USF. J Biol Chem. 1999 Jan
8;274(2):595-606
Wechsler DS, Shelly CA, Petroff CA, Dang CV. MXI1, a
putative tumor suppressor gene, suppresses growth of human
glioblastoma cells. Cancer Res. 1997 Nov 1;57(21):4905-12
This article should be referenced as such:
Atkin NB. MXI1 (MAX interactor 1). Atlas Genet Cytogenet
Oncol Haematol. 1999; 3(4):185-186.
Schreiber-Agus N, DePinho RA. Repression by the Mad(Mxi1)Sin3 complex. Bioessays. 1998 Oct;20(10):808-18
Atlas Genet Cytogenet Oncol Haematol. 1999; 3(4)
186